
Chromosomal disorders, including trisomies, deletions, duplications, and structural rearrangements, account for a significant proportion of congenital anomalies, intellectual disability, and pregnancy loss. Non-invasive prenatal testing has transformed screening, while management focuses on multidisciplinary support for associated comorbidities. Gene therapy and pharmacological trials in Down syndrome and other aneuploidies are emerging.